{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T09:30:33Z","timestamp":1784367033381,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003569","name":"Korea Ministry of Food and Drug Safety","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003569","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-inpractice.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jaip.2021.03.054","type":"journal-article","created":{"date-parts":[[2021,4,19]],"date-time":"2021-04-19T10:39:23Z","timestamp":1618828763000},"page":"3442-3449.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Reintroduction of Antituberculous Drugs in Patients with Antituberculous Drug-Related Drug Reaction with Eosinophilia and Systemic Symptoms"],"prefix":"10.1016","volume":"9","author":[{"given":"Ji Hyun","family":"Oh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Suk","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-Hee","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Joon","family":"Yim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2317-4201","authenticated-orcid":false,"given":"Hye-Ryun","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2021.03.054_bib1","unstructured":"Global Tuberculosis Programme. Global Tuberculosis Report 2020. Geneva: World Health Organization; 2020."},{"key":"10.1016\/j.jaip.2021.03.054_bib2","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.amjmed.2011.01.017","article-title":"The DRESS syndrome: a literature review","volume":"124","author":"Cacoub","year":"2011","journal-title":"Am J Med"},{"key":"10.1016\/j.jaip.2021.03.054_bib3","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.burns.2013.03.011","article-title":"27 years of a single burn centre experience with Stevens-Johnson syndrome and toxic epidermal necrolysis: analysis of mortality risk for causative agents","volume":"39","author":"Weinand","year":"2013","journal-title":"Burns"},{"key":"10.1016\/j.jaip.2021.03.054_bib4","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/all.12161","article-title":"Desensitization in delayed drug hypersensitivity reactions\u2014an EAACI position paper of the Drug Allergy Interest Group","volume":"68","author":"Scherer","year":"2013","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.054_bib5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/gim.2014.195","article-title":"An effective strategy to prevent allopurinol-induced hypersensitivity by HLA typing","volume":"17","author":"Jung","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.jaip.2021.03.054_bib6","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1365-2133.2006.07704.x","article-title":"Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist?","volume":"156","author":"Kardaun","year":"2007","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.03.054_bib7","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1097\/00002030-200109280-00014","article-title":"Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"15","author":"Fagot","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.jaip.2021.03.054_bib8","doi-asserted-by":"crossref","first-page":"395","DOI":"10.4168\/aard.2013.1.4.395","article-title":"Successful desensitization for antitubercular drugs","volume":"1","author":"Lee","year":"2013","journal-title":"Allergy Asthma Respir Dis"},{"key":"10.1016\/j.jaip.2021.03.054_bib9","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4168\/aard.2015.3.4.297","article-title":"Successful readministration of second-line antituberculous agents in a patient with near-fatal drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome","volume":"3","author":"Moon","year":"2015","journal-title":"Allergy Asthma Respir Dis"},{"key":"10.1016\/j.jaip.2021.03.054_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/cod.12432","article-title":"European Society of Contact Dermatitis guideline for diagnostic patch testing\u2014recommendations on best practice","volume":"73","author":"Johansen","year":"2015","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2021.03.054_bib11","doi-asserted-by":"crossref","first-page":"836","DOI":"10.4103\/0378-6323.120751","article-title":"Patch testing in cutaneous adverse drug reactions: methodology, interpretation, and clinical relevance","volume":"79","author":"Mahajan","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.1016\/j.jaip.2021.03.054_bib12","first-page":"287","article-title":"Terminology of contact dermatitis","volume":"50","author":"Wilkinson","year":"1970","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaip.2021.03.054_bib13","doi-asserted-by":"crossref","first-page":"1702678","DOI":"10.1183\/13993003.02678-2017","article-title":"ERS\/ECDC Statement: European Union standards for tuberculosis care, 2017 update","volume":"51","author":"Migliori","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2021.03.054_bib14","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1016\/j.jaip.2019.05.034","article-title":"Sulfonamide hypersensitivity: fact and fiction","volume":"7","author":"Khan","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.054_bib15","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaci.2018.10.030","article-title":"Controversies in drug allergy: testing for delayed reactions","volume":"143","author":"Phillips","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.054_bib16","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/cod.13462","article-title":"Hypersensitivity to antibiotics in drug reaction with eosinophilia and systemic symptoms (DRESS) from other culprits","volume":"82","author":"Santiago","year":"2020","journal-title":"Contact Dermatitis"},{"key":"10.1016\/j.jaip.2021.03.054_bib17","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaip.2019.06.009","article-title":"Multiple drug hypersensitivity syndrome in a large database","volume":"8","author":"Landry","year":"2020","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.054_bib18","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.1346-8138.2010.01142.x","article-title":"Drug hypersensitivity: flare-up reactions, cross-reactivity and multiple drug hypersensitivity","volume":"38","author":"Pichler","year":"2011","journal-title":"J\u00a0Dermatol"},{"key":"10.1016\/j.jaip.2021.03.054_bib19","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1016\/j.jaip.2017.11.021","article-title":"Antituberculosis drug-associated DRESS: a case series","volume":"6","author":"Allouchery","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.054_bib20","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1398-9995.2011.02720.x","article-title":"Multiple drug hypersensitivity: normal Treg cell function but enhanced in\u00a0vivo activation of drug-specific T cells","volume":"67","author":"Daubner","year":"2012","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.054_bib21","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000458725","article-title":"Multiple drug hypersensitivity","volume":"172","author":"Pichler","year":"2017","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaip.2021.03.054_bib22","first-page":"293","article-title":"Multiple drug hypersensitivity\u2014proof of multiple drug hypersensitivity by patch and lymphocyte transformation tests","volume":"15","author":"Gex-Collet","year":"2005","journal-title":"J\u00a0Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.054_bib23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1111\/bjd.12125","article-title":"A\u00a0multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reactions","volume":"168","author":"Barbaud","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaip.2021.03.054_bib24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.jaip.2017.02.014","article-title":"Practical management of antibiotic hypersensitivity in 2017","volume":"5","author":"Macy","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.054_bib25","first-page":"1246","article-title":"Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response","volume":"43","author":"Yun","year":"2013"},{"key":"10.1016\/j.jaip.2021.03.054_bib26","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1378\/chest.98.6.1518","article-title":"Rapid oral desensitization to isoniazid and rifampin","volume":"98","author":"Holland","year":"1990","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2021.03.054_bib27","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1034\/j.1398-9995.2003.00152.x","article-title":"Rapid oral desensitization to isoniazid, rifampin, and ethambutol","volume":"58","author":"Kim","year":"2003","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2021.03.054_bib28","first-page":"119","article-title":"Two cases of rifampin desensitization in AIDS patients with rifampin hypersensitivity","volume":"22","author":"Seo","year":"2002","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2021.03.054_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4168\/aard.2017.5.2.111","article-title":"DRESS (drug reaction with eosinophilia and systemic symptom) syndrome caused by both first-line and second-line antitubercular medications: a case report with a brief literature review","volume":"5","author":"Hwang","year":"2017","journal-title":"Allergy Asthma Respir Dis"},{"key":"10.1016\/j.jaip.2021.03.054_bib30","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1159\/000078583","article-title":"Successful desensitization to fixed drug eruption: the presence of CD25+CD4+ T cells in the epidermis of fixed drug eruption lesions may be involved in the induction of desensitization","volume":"209","author":"Teraki","year":"2004","journal-title":"Dermatology"},{"key":"10.1016\/j.jaip.2021.03.054_bib31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jcf.2011.02.002","article-title":"Rapid desensitization for non-immediate reactions in patients with cystic fibrosis","volume":"10","author":"Whitaker","year":"2011","journal-title":"J\u00a0Cyst Fibros"},{"key":"10.1016\/j.jaip.2021.03.054_bib32","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jaip.2014.03.016","article-title":"Successful desensitization protocol for delayed cutaneous eruption to temozolomide","volume":"2","author":"Clayton","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2021.03.054_bib33","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/jcpt.12827","article-title":"Rapid subcutaneous desensitization for the management of delayed hypersensitivity reactions to omalizumabA case report","volume":"44","author":"Gan","year":"2019","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.jaip.2021.03.054_bib34","first-page":"699","article-title":"Desensitization therapy for allergic reactions of antituberculous drugs\u2014evaluation of desensitization therapy according to the guideline of the Japanese Society for Tuberculosis [in Japanese]","volume":"75","author":"Kobashi","year":"2000","journal-title":"Kekkaku"},{"key":"10.1016\/j.jaip.2021.03.054_bib35","first-page":"1389","article-title":"Anti-tuberculosis chemotherapy and management of adverse reactions [in Japanese]","volume":"69","author":"Kuwabara","year":"2011","journal-title":"Nihon Rinsho"},{"key":"10.1016\/j.jaip.2021.03.054_bib36","first-page":"521","article-title":"Desensitization therapy for antituberculous drugs [in Japanese]","volume":"75","author":"Kobashi","year":"2000","journal-title":"Kekkaku"}],"updated-by":[{"DOI":"10.1016\/j.jaip.2021.09.010","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000}}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821004414?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219821004414?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T09:45:18Z","timestamp":1631007918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219821004414"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S2213219821004414"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2021.03.054","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.jaip.2021.09.010","asserted-by":"object"}]},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reintroduction of Antituberculous Drugs in Patients with Antituberculous Drug-Related Drug Reaction with Eosinophilia and Systemic Symptoms","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2021.03.054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}